For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Competition Intensifies on Market for Antidepressants
April 29, 2002
- Companies' Responsibility for Promotion of Medical Safety Clarified
April 29, 2002
- We Are Open to Strategic Alliance: Mr Wright of AstraZeneca
April 29, 2002
- Hitachi Medical: Digital Ultrasound Diagnostic System
April 22, 2002
- Fujisawa Launches Protopic in Germany
April 22, 2002
- Olympus: VISERA Video System for Endoscopy
April 22, 2002
- AnGes MG Newly Agrees Agreement with Daiichi on HGF Gene Therapy
April 22, 2002
- Genzyme Promotes 4-Marker Maternal Serum Screening Test
April 22, 2002
- Nippon Roche, Chugai to Copromote Kytril
April 22, 2002
- Takeda: HICEE WHITE 2
April 22, 2002
- BUSINESS NEWS IN BRIEF
April 22, 2002
- Hac Kimisawa: Sales Up 6.7% to \144 Bil.
April 22, 2002
- WLJ: FY2001 Sales Up 8.8% to \46.2 Bil.
April 22, 2002
- Kirindo: Consolidated Sales Jump to \33 Bil.
April 22, 2002
- Teijin: Drug Sales, Profits to Plummet in FY2002
April 22, 2002
- WORLD NEWS IN BRIEF
April 22, 2002
- Hisamitsu: FY2001 Sales Up 6.6% to \69.5 Bil.
April 22, 2002
- Bayer Group to Increase Sales in Japan to \300 Bil. by 2004: Dr Portoff
April 22, 2002
- Pharmacia Starts Joint Research with Keio Univ.
April 22, 2002
- Pharmaceutical Industry Vision Drafted by Korosho
April 22, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…